What's in Jean-Pierre Van geertruyden's pipeline?

Jean-Pierre Van geertruyden has 3 drugs in our index: 0 marketed, 0 filed, 3 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Jean-Pierre Van geertruyden's portfolio?

Top competitors by shared drug class: Merck Sharp & Dohme LLC, AstraZeneca, Biomed Industries, Inc., GlaxoSmithKline, Sanofi.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/jean-pierre-van-geertruyden.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Jean-Pierre Van geertruyden — Portfolio Competitive Intelligence Brief

Jean-Pierre Van geertruyden pipeline: 0 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
MVA-BN standard regimen	MVA-BN standard regimen	phase 3	Live attenuated viral vaccine	Monkeypox virus antigens	Immunology / Infectious Disease
MVA-BN half-dose regimen	MVA-BN half-dose regimen	phase 3	Live attenuated viral vaccine	Monkeypox virus antigens (L1, A29, I3, I4, I5 proteins)	Immunology / Infectious Disease
AV2	AV2	phase 3	SGLT2 inhibitor	SGLT2	Diabetes

Therapeutic area mix

Immunology / Infectious Disease · 2
Diabetes · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Merck Sharp & Dohme LLC · 2 shared drug classes
AstraZeneca · 2 shared drug classes
Biomed Industries, Inc. · 2 shared drug classes
GlaxoSmithKline · 2 shared drug classes
Sanofi · 2 shared drug classes
Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
AceLink Therapeutics, Inc. · 1 shared drug class
AJU Pharm Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Jean-Pierre Van geertruyden:

Cite this brief

Drug Landscape (2026). Jean-Pierre Van geertruyden — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jean-pierre-van-geertruyden. Accessed 2026-05-16.